Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05504668
Other study ID # 50BP1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 20, 2019
Est. completion date February 2, 2022

Study information

Verified date August 2022
Source Northumbria University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigated the effects of a proprietorial herbal supplement, Turmeric Brainwave (now Mind focus), on cognition, mood and the microbiome in older adults experiencing subjective memory decline, following 90 days supplementation.


Description:

The primary aim of this randomised, double blind, placebo-controlled, parallel groups study was to assess the effects of a daily dose of Turmeric Brainwaves, versus placebo, both acutely and following 90 days consumption. Effects were to be assessed in 55-75 year old males and females who reported that their memory now was worse than when in their 20's. Effects were assessed via cognitive (including COMPASS and Cognimapp as well as 2 real-world long-term memory tasks (location-action (AKA Prospective Remembering Video Procedure (PRVP)) and recall of facts)) and mood (using visual analogue scales) outcomes and, additionally, stool and urine samples collected at the beginning and the end of the trial period assessed the microfloral community of the gut and urinary metabolome.


Recruitment information / eligibility

Status Completed
Enrollment 174
Est. completion date February 2, 2022
Est. primary completion date February 2, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 75 Years
Eligibility Inclusion Criteria: - 55-75 years at time of enrolment - Answers yes to the question 'would you say that your memory now is worse now than it used to be in your 20's?' Exclusion Criteria: - Pre-existing medical condition/illnesses which would impact taking part in the study The explicit exceptions to this were controlled (medicated) arthritis, asthma, hay fever, high cholesterol and reflux-related conditions. Other, unforeseen, exceptions were considered on a case-by-case basis; i.e. participants may have progressed to screening if they had a condition/illness which would not interact with the active treatments or impede performance. - Currently taking prescription medications The explicit exceptions to this were contraceptive and hormone replacement treatments for female participants where symptoms were stable and treatment would not change during the course of the study, those medications used in the treatment of arthritis, high cholesterol and reflux-related conditions and those taken 'as needed' in the treatment of asthma and hay fever. As above, there may have been other instances of permitted medication use where no interaction with the active treatments was anticipated. - High blood pressure (BP; systolic over 159 mm Hg or diastolic over 99 mm Hg) - Body Mass Index (BMI) outside of the range 18.5-30 kg/m2 - Pregnant, seeking to become pregnant or lactating - Learning and/or behavioural difficulties such as dyslexia or Attention Deficit Hyperactivity Disorder (ADHD) - Visual impairments not corrected with glasses or contact lenses (including colour-blindness) - Smoking (including vaping) - Excessive caffeine intake (>500 mg per day) - Clinically diagnosed food intolerances/sensitivities - Antibiotic, prebiotic or probiotic (including drinks; e.g. Yakult or Actimel) use within the past 8 weeks - Health conditions preventing fulfilment of the study requirements (this included non-diagnosed conditions for which no medication was taken) - Inability to complete all of the study assessments - Currently participating in other clinical or nutrition intervention studies, or had in the past 4 weeks (8 weeks if a probiotic study) - Diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months - Diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months - Suffering from frequent migraines that require medication (more than or equal to 1 per month) - Sleep disturbances (including night-shift work) and/or are taking sleep aid medication - Any known active infections - Does not have a bank account (required for payment) - Are non-compliant with regards treatment consumption

Study Design


Intervention

Dietary Supplement:
Turmeric Brainwave
A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.

Locations

Country Name City State
United Kingdom Brain Performance and Nutrition Research Centre Newcastle Upon Tyne Tyne And Wear

Sponsors (2)

Lead Sponsor Collaborator
Northumbria University Pukka Herbs Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cognitive function (lab-based) This outcome will be assessed via changes on the cognitive task outcomes (measured via COMPASS). COMPASS is a proprietorial software platform for delivering a range of cognitive tasks; assessing domains like memory and attention, with tasks scored for accuracy (% correct) and speed (msec). 90 days
Secondary Cognitive function (remote) This outcome will be assessed via changes on the cognitive task outcomes (measured via Cognimapp). Cognimapp is a proprietorial software platform for delivering a range of cognitive tasks via mobile phone; assessing domains like memory and attention, with tasks scored for accuracy (% correct) and speed (msec). 90 days
Secondary Mood (Anxiety) This outcome will be assessed via changes on the Generalised Anxiety Disorder 7 (GAD 7) questionnaire. This questionnaire comprises 7 items which are scored from 0 (not at all) to 3 (nearly every day) with a higher score indicating greater anxiety. 90 days
Secondary Mood (General) This outcome will be assessed via changes on Visual Analogue Scales (VAS). This VAS is a 100 mm line with mood related adjectives anchoring each end of the line. This is scored from mm distance along the line; with a higher score indicating greater feeling of that mood facet. 90 days
Secondary Prospective memory This facet of memory is assessed by the Prospective Remembering Video Procedure (PRVP) which is an 18-item list of locations and actions depicted within a 10-minute video. Participants must encode these locations and actions and recall them when watching this video at a later date. 90 days
Secondary Delayed recall This is a real-world recall of 10 facts, created by the principal investigator for the purposes of this study, which participants encode at the start of the trial and must recall at the end. 90 days
Secondary Gut microbiota This will be assessed by any shifts in gut microbial species from a stool sample collected at the start of the trial compared to the stool sample taken at the end. 90 days
Secondary Urinary metabolome This will be assessed by any shifts in markers identified within the urinary metabolome from a urine sample collected at the start of the trial compared to the urine sample taken at the end. 90 days
See also
  Status Clinical Trial Phase
Completed NCT05712005 - Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
Completed NCT05343208 - Effectiveness of Online Therapy to Prevent Burnout N/A
Active, not recruiting NCT05143294 - Conectar Jugando: Board Games in Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT05267730 - Conectar Jugando: Board Games in Rural Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT03987477 - Online Intervention to Modify Interpretation Biases in Depression N/A
Completed NCT03695003 - Cognitive Effects of Sage in Healthy Humans N/A
Completed NCT05075850 - Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Completed NCT03689348 - Acute and Chronic Effects of Avena Sativa on Cognition and Stress N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Active, not recruiting NCT05229705 - Exercise in Older Adults at Risk for Type 2 Diabetes N/A
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Terminated NCT03337282 - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Completed NCT03657537 - Effects of Ketone Bodies on Cognition in Type 2 Diabetes Phase 1
Completed NCT05543811 - The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology N/A
Recruiting NCT05699226 - Amplitude Titration to Improve ECT Clinical Outcomes N/A
Recruiting NCT05026541 - Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators N/A
Active, not recruiting NCT03255499 - Efficacy of the MovinCog Intervention in Children N/A
Not yet recruiting NCT06252376 - Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD N/A